Supplementary Figure S4. PK and anti-tumor activity of FGF401 in rats. A. PK profile of FGF401 in rats upon i.v. administration. Drug concentrations were determined in blood samples collected at 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 24 and 48 hours. Shown are means ± SEM, n=4. The grey line represents the terminal elimination phase of the drug using a non-compartmental analysis, with a terminal half-life estimated to be 4.4 hours. B. Female nude rats bearing HuH7 subcutaneous xenografts were treated with FGF401 or vehicle control p.o. bid at indicated doses. Values are mean ± SEM, n=5 per group. *p<0.05 vs vehicle using Kruskal-Wallis (Dunn's post hoc) on ΔTVol. C. Drug concentrations were determined in blood samples collected at 1, 2, 4, 8 and 12h post first dose. Data show mean values ± SD (n=2) for total drug concentration. IC_{50} (2.1 nM) and IC_{90} (52.1 nM) levels from the in vivo mouse PD model are depicted in the plots.

A



B



C



Supplementary Fig. S4